Arrivent biopharma inc AVBP.US Overview Analysis
AVBP AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
With insufficient quarterly financial data released by the company, we're unable to provide a rating.
AVBP Current Performance
0.56%
Arrivent biopharma inc
0.23%
Avg of Sector
0.43%
S&P500
Top 10 High Relevance to AVBP
- BBIO Bridgebio pharma incValue 2Trend 4Swing Trading 4Whale Interest 4Dividend 1See more
AVBP Profile
ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The Company is focused on maximizing the potential of its lead development candidate, firmonertinib, and advancing a pipeline of novel therapeutics, such as antibody drug conjugates (ADCs), through approval and commercialization. Firmonertinib is an oral, highly brain-penetrant, and broadly active mutation-selective epidermal growth factor receptor (EGFR) inhibitor active against both classical and uncommon EGFR mutations, including PACC and exon 20 insertion mutations. Firmonertinib is also being studied in a clinical combination study targeting advanced or metastatic NSCLC patients with EGFR classical mutations. It is developing ARR-217, an ADC for the treatment of gastrointestinal cancers. Its ARR-002 candidate is focused on the treatment of solid tumors.